# Minerva Neurosciences Inc (NERV)

Source: https://www.quantisnow.com/company/NERV
Generated: 2026-11-12T01:25:11.192Z

- Ticker: NERV
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Pharmaceutical Preparations
- IPO year: 2014
- SEC CIK: 0001598646
- Website: minervaneurosciences.com

## About

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone, a compound in Phase III clinical trial for the treatment of schizophrenia; and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. Minerva Neurosciences, Inc. has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. The company was formerly known as Cyrenaic Pharmaceuticals, Inc. and changed its name to Minerva Neurosciences, Inc. in 2013. Minerva Neurosciences, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.

## Latest NERV news and filings

- 2026-11-06 21:00 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Minerva Neurosciences Inc](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-minerva-neurosciences-inc-6778767)
- 2026-11-06 14:10 UTC [SEC Form 8-K] [Minerva Neurosciences Inc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits](https://www.quantisnow.com/insight/minerva-neurosciences-inc-filed-sec-form-8-k-results-of-operations-6778246)
- 2026-11-06 14:00 UTC [Minerva Neurosciences Provides Third Quarter 2026 Financial Results and Business Updates](https://www.quantisnow.com/insight/minerva-neurosciences-provides-third-quarter-2026-financial-results-and-business-6778219)
- 2026-11-03 23:05 UTC [SEC Form 4] [Director Kaul Inderjit was granted 2,328 stock options (SEC Form 4)](https://www.quantisnow.com/insight/director-kaul-inderjit-was-granted-2328-stock-options-sec-form-6770681)
- 2026-10-29 11:00 UTC [Conference Announcement] [Minerva Neurosciences to Participate in 2026 Jefferies Global Healthcare Conference in London](https://www.quantisnow.com/insight/minerva-neurosciences-to-participate-in-2026-jefferies-global-healthcare-conference-6762305)
- 2026-10-28 11:00 UTC [Minerva Neurosciences to Host In-Person KOL Event to Discuss Roluperidone for Negative Symptoms of Schizophrenia](https://www.quantisnow.com/insight/minerva-neurosciences-to-host-in-person-kol-event-to-discuss-roluperidone-6760382)
- 2026-08-28 12:00 UTC [Conference Announcement] [Minerva Neurosciences to Participate in Two Upcoming Investor Conferences](https://www.quantisnow.com/insight/minerva-neurosciences-to-participate-in-two-upcoming-investor-conferences-6697924)
- 2026-08-20 20:40 UTC [SEC Form 3] [New insider Reilly Joseph H. claimed ownership of 20,872 shares (SEC Form 3)](https://www.quantisnow.com/insight/new-insider-reilly-joseph-h-claimed-ownership-of-20872-shares-6690285)
- 2026-08-20 20:38 UTC [SEC Form 3] [New insider Aliquo Anthony claimed ownership of 1,683 shares (SEC Form 3)](https://www.quantisnow.com/insight/new-insider-aliquo-anthony-claimed-ownership-of-1683-shares-sec-6690282)
- 2026-08-14 12:14 UTC [Analyst Upgrade] [Minerva Neurosciences upgraded by Jefferies with a new price target](https://www.quantisnow.com/insight/minerva-neurosciences-upgraded-by-jefferies-with-a-new-price-target-6681928)
- 2026-08-14 10:05 UTC [Amendment: SEC Form SCHEDULE 13G/A filed by Minerva Neurosciences Inc](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13ga-filed-by-minerva-neurosciences-inc-6681678)
- 2026-08-13 21:17 UTC [Amendment: SEC Form SCHEDULE 13G/A filed by Minerva Neurosciences Inc](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13ga-filed-by-minerva-neurosciences-inc-6681293)
- 2026-08-12 20:05 UTC [SEC Form 8-K] [SEC Form 8-K filed by Minerva Neurosciences Inc](https://www.quantisnow.com/insight/sec-form-8-k-filed-by-minerva-neurosciences-inc-6677823)
- 2026-08-07 11:30 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Minerva Neurosciences Inc](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-minerva-neurosciences-inc-6670569)
- 2026-08-07 11:13 UTC [SEC Form 8-K] [Minerva Neurosciences Inc filed SEC Form 8-K: Results of Operations and Financial Condition](https://www.quantisnow.com/insight/minerva-neurosciences-inc-filed-sec-form-8-k-results-of-operations-6670542)
- 2026-08-07 11:00 UTC [Public Offering] [Minerva Neurosciences Provides Second Quarter 2026 Financial Results and Business Updates](https://www.quantisnow.com/insight/minerva-neurosciences-provides-second-quarter-2026-financial-results-and-business-6670481)
- 2026-08-03 22:05 UTC [SEC Form 4] [SEC Form 4 filed by Director Kaul Inderjit](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-kaul-inderjit-6660456)
- 2026-07-08 11:51 UTC [Amendment: SEC Form SCHEDULE 13G/A filed by Minerva Neurosciences Inc](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13ga-filed-by-minerva-neurosciences-inc-6630877)
- 2026-06-05 22:00 UTC [SEC Form 4] [SEC Form 4 filed by CEO Luthringer Remy](https://www.quantisnow.com/insight/sec-form-4-filed-by-ceo-luthringer-remy-6592077)
- 2026-06-05 22:00 UTC [SEC Form 4] [SEC Form 4 filed by Director Laghrissi-Thode Fouzia](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-laghrissi-thode-fouzia-6592076)
- 2026-06-05 22:00 UTC [SEC Form 4] [SEC Form 4 filed by SVP, CFO and Secretary Ahlholm Frederick W](https://www.quantisnow.com/insight/sec-form-4-filed-by-svp-cfo-and-secretary-ahlholm-6592075)
- 2026-06-05 22:00 UTC [SEC Form 4] [SEC Form 4 filed by Director Kupfer David](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-kupfer-david-6592074)
- 2026-06-05 22:00 UTC [SEC Form 4] [SEC Form 4 filed by Director Hasler Hans Peter](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-hasler-hans-peter-6592072)
- 2026-06-05 22:00 UTC [SEC Form 4] [SEC Form 4 filed by Director Van Heek G Jan](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-van-heek-g-jan-6592071)
- 2026-06-05 22:00 UTC [SEC Form 4] [SEC Form 4 filed by Director Kaul Inderjit](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-kaul-inderjit-6592070)
- 2026-06-04 20:05 UTC [SEC Form 8-K] [Minerva Neurosciences Inc filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Material Modification to Rights of Security Holders](https://www.quantisnow.com/insight/minerva-neurosciences-inc-filed-sec-form-8-k-amendments-to-articles-6589283)
- 2026-06-01 20:05 UTC [Minerva Neurosciences Establishes Scientific Advisory Board to Advance Development of Roluperidone and Future Pipeline Programs](https://www.quantisnow.com/insight/minerva-neurosciences-establishes-scientific-advisory-board-to-advance-development-of-6581504)
- 2026-05-27 20:18 UTC [SEC Form 8-K] [SEC Form 8-K filed by Minerva Neurosciences Inc](https://www.quantisnow.com/insight/sec-form-8-k-filed-by-minerva-neurosciences-inc-6574936)
- 2026-05-27 20:14 UTC [SEC Form 424B5] [SEC Form 424B5 filed by Minerva Neurosciences Inc](https://www.quantisnow.com/insight/sec-form-424b5-filed-by-minerva-neurosciences-inc-6574872)
- 2026-05-18 20:05 UTC [Conference Announcement] [Minerva Neurosciences to Participate in the 2026 Jefferies Global Healthcare Conference](https://www.quantisnow.com/insight/minerva-neurosciences-to-participate-in-the-2026-jefferies-global-healthcare-6560046)
- 2026-05-15 15:43 UTC [SEC Form SCHEDULE 13G filed by Minerva Neurosciences Inc](https://www.quantisnow.com/insight/sec-form-schedule-13g-filed-by-minerva-neurosciences-inc-6556479)
- 2026-05-15 10:07 UTC [Amendment: SEC Form SCHEDULE 13G/A filed by Minerva Neurosciences Inc](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13ga-filed-by-minerva-neurosciences-inc-6555427)
- 2026-05-05 12:30 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Minerva Neurosciences Inc](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-minerva-neurosciences-inc-6531043)
- 2026-05-05 12:09 UTC [SEC Form 8-K] [Minerva Neurosciences Inc filed SEC Form 8-K: Results of Operations and Financial Condition](https://www.quantisnow.com/insight/minerva-neurosciences-inc-filed-sec-form-8-k-results-of-operations-6530958)
- 2026-05-05 12:00 UTC [Leadership Update] [Minerva Neurosciences Provides First Quarter 2026 Financial Results and Business Updates](https://www.quantisnow.com/insight/minerva-neurosciences-provides-first-quarter-2026-financial-results-and-business-6530882)
- 2026-04-23 11:02 UTC [SEC Form DEFA14A] [SEC Form DEFA14A filed by Minerva Neurosciences Inc](https://www.quantisnow.com/insight/sec-form-defa14a-filed-by-minerva-neurosciences-inc-6511484)
- 2026-04-23 11:00 UTC [SEC Form DEF 14A] [SEC Form DEF 14A filed by Minerva Neurosciences Inc](https://www.quantisnow.com/insight/sec-form-def-14a-filed-by-minerva-neurosciences-inc-6511470)
- 2026-04-22 20:55 UTC [SEC Form 4] [SEC Form 4 filed by O'Connor James Joseph](https://www.quantisnow.com/insight/sec-form-4-filed-by-oconnor-james-joseph-6510822)
- 2026-04-22 20:53 UTC [SEC Form 3] [SEC Form 3 filed by new insider O'Connor James Joseph](https://www.quantisnow.com/insight/sec-form-3-filed-by-new-insider-oconnor-james-joseph-6510814)
- 2026-04-15 12:09 UTC [Analyst Coverage Initiated] [Citizens initiated coverage on Minerva Neurosciences with a new price target](https://www.quantisnow.com/insight/citizens-initiated-coverage-on-minerva-neurosciences-with-a-new-price-6500609)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/NERV
- Earnings history: https://www.quantisnow.com/earnings/NERV
- Dividend history: https://www.quantisnow.com/dividends/NERV
- Insider transactions: https://www.quantisnow.com/insiders/NERV
- Options chain: https://www.quantisnow.com/options/NERV
- SEC 8-K filings only: https://www.quantisnow.com/company/NERV/8-k
- RSS and alerts for NERV: https://www.quantisnow.com/docs/rss-feeds.md